Scisparc

Scisparc ROCE

The Return on Capital Employed (ROCE) of Scisparc (SPRC) as of Nov 21, 2026 is -169.98 %. In the previous year, Return on Capital Employed (ROCE) was -81.84 % — a change of 107.69% (lower).

ROCE

-169.98 %

YoY

107.69%

Last updated:

In 2025, Scisparc's return on capital employed (ROCE) was -169.98 %, a 107.69% increase from the -81.84 % ROCE in the previous year.

The Scisparc ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-12,615.58 USD
Jan 1, 2019
-29,342.86 USD
Jan 1, 2020
-230.28 USD
Jan 1, 2021
-70.85 USD
Jan 1, 2022
-114.44 USD
Jan 1, 2023
-60.22 USD
Jan 1, 2024
-81.84 USD
Jan 1, 2025
-169.98 USD
The Scisparc ROCE history
YEARROCEYoY
-169.98 %+107.69%
-81.84 %+35.91%
-60.22 %-47.38%
-114.44 %+61.52%
-70.85 %-69.23%
-230.28 %-99.22%
-29,342.86 %+132.59%
-12,615.58 %+18,292.79%
-68.59 %-80.33%
-348.71 %+57.76%
-221.03 %-114.46%
1,528.25 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scisparc Stock analysis

What does Scisparc do? SciSparc Ltd develops cannabinoid-based pharmaceuticals including THX-110 for Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for infectious diseases; and THX-160 for pain. The company monetizes through drug development programs targeting specific medical conditions, with pharmaceutical companies and research institutions as primary buyers of these development assets. The firm's revenue streams derive from licensing agreements and partnerships with biopharmaceutical entities seeking to advance cannabinoid-based therapies for unmet medical needs. SciSparc focuses on repurposing Dronabinol into multiple therapeutic applications, creating a diversified portfolio of drug candidates. Its products target neurological disorders, sleep disorders, and infectious diseases, appealing to healthcare providers and patients requiring innovative treatments. The company's business model relies on generating revenue through the sale of development-stage drug assets to larger pharmaceutical firms rather than direct patient sales. The firm's pipeline includes four distinct drug candidates, each addressing different medical conditions. THX-110 targets Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 addresses Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 targets infectious diseases; and THX-160 focuses on pain management. These assets are marketed to biopharmaceutical companies as potential additions to their therapeutic portfolios. Scisparc is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Scisparc's Return on Capital Employed (ROCE)

Scisparc's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Scisparc's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Scisparc's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Scisparc’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Scisparc stock

Return on Capital Employed (ROCE) of Scisparc is -169.98 % in 2025.

Return on Capital Employed (ROCE) of Scisparc changed from -81.84 % to -169.98 %, representing a 107.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Scisparc since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Scisparc with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Scisparc

All Key Metrics — Scisparc